Spurring Innovation While Economizing On R&D Spending Remains Industry-Wide Challenge
Cash is still “cheap” but biopharma M&A continues to move slowly – mid-cap industry execs tell “The Pink Sheet” partly because there is so much competition to acquire the best assets. Meanwhile, most companies are economizing on R&D even as they strive to develop the products that will carry them into the next decade.
You may also be interested in...
Shire Sheds Dermagraft; Exits Regenerative Medicine
The Irish specialty pharma has divested an underperforming unit, but not without a significant write-off. Yet, investors and analysts applaud the decision.
Shire’s ViroPharma Purchase Aims To Build Rare Disease Giant
Shire is buying ViroPharma at a steep premium to acquire its pipeline assets, notably C1 esterase inhibitor Cinryze, which the London-listed specialty pharma plans to expand internationally, initially to treat hereditary angioedema and later for other rare diseases.
Will Saunders Bring Transformation To Forest?
The specialty pharma long has been scrutinized for its decisions regarding the patent cliff and business development. Now, a new CEO will have the chance to keep the company on its current course or mirror the transformations he’s put in motion at other companies.